Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019

Patrick A. Brown, Matthew Wieduwilt, Aaron Logan, Daniel J. DeAngelo, Eunice S. Wang, Amir Fathi, Ryan D. Cassaday, Mark R Litzow, Anjali Advani, Patricia Aoun, Bhavana Bhatnagar, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Peter F. Coccia, Steven E. Coutre, Nitin Jain, Suzanne Kirby, Arthur Liu, Stephanie MassaroRyan J. Mattison, Olalekan Oluwole, Nikolaos Papadantonakis, Jae Park, Jeffrey E. Rubnitz, Geoffrey L. Uy, Kristina M. Gregory, Ndiya Ogba, Bijal Shah

Research output: Contribution to journalArticle

Abstract

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

Original languageEnglish (US)
Pages (from-to)414-423
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume17
Issue number5
DOIs
StatePublished - May 1 2019
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Guidelines
Residual Neoplasm
Therapeutics
Comorbidity
Leukemia

ASJC Scopus subject areas

  • Oncology

Cite this

Brown, P. A., Wieduwilt, M., Logan, A., DeAngelo, D. J., Wang, E. S., Fathi, A., ... Shah, B. (2019). Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. Journal of the National Comprehensive Cancer Network : JNCCN, 17(5), 414-423. https://doi.org/10.6004/jnccn.2019.0024

Guidelines Insights : Acute Lymphoblastic Leukemia, Version 1.2019. / Brown, Patrick A.; Wieduwilt, Matthew; Logan, Aaron; DeAngelo, Daniel J.; Wang, Eunice S.; Fathi, Amir; Cassaday, Ryan D.; Litzow, Mark R; Advani, Anjali; Aoun, Patricia; Bhatnagar, Bhavana; Boyer, Michael W.; Bryan, Teresa; Burke, Patrick W.; Coccia, Peter F.; Coutre, Steven E.; Jain, Nitin; Kirby, Suzanne; Liu, Arthur; Massaro, Stephanie; Mattison, Ryan J.; Oluwole, Olalekan; Papadantonakis, Nikolaos; Park, Jae; Rubnitz, Jeffrey E.; Uy, Geoffrey L.; Gregory, Kristina M.; Ogba, Ndiya; Shah, Bijal.

In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 17, No. 5, 01.05.2019, p. 414-423.

Research output: Contribution to journalArticle

Brown, PA, Wieduwilt, M, Logan, A, DeAngelo, DJ, Wang, ES, Fathi, A, Cassaday, RD, Litzow, MR, Advani, A, Aoun, P, Bhatnagar, B, Boyer, MW, Bryan, T, Burke, PW, Coccia, PF, Coutre, SE, Jain, N, Kirby, S, Liu, A, Massaro, S, Mattison, RJ, Oluwole, O, Papadantonakis, N, Park, J, Rubnitz, JE, Uy, GL, Gregory, KM, Ogba, N & Shah, B 2019, 'Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 17, no. 5, pp. 414-423. https://doi.org/10.6004/jnccn.2019.0024
Brown, Patrick A. ; Wieduwilt, Matthew ; Logan, Aaron ; DeAngelo, Daniel J. ; Wang, Eunice S. ; Fathi, Amir ; Cassaday, Ryan D. ; Litzow, Mark R ; Advani, Anjali ; Aoun, Patricia ; Bhatnagar, Bhavana ; Boyer, Michael W. ; Bryan, Teresa ; Burke, Patrick W. ; Coccia, Peter F. ; Coutre, Steven E. ; Jain, Nitin ; Kirby, Suzanne ; Liu, Arthur ; Massaro, Stephanie ; Mattison, Ryan J. ; Oluwole, Olalekan ; Papadantonakis, Nikolaos ; Park, Jae ; Rubnitz, Jeffrey E. ; Uy, Geoffrey L. ; Gregory, Kristina M. ; Ogba, Ndiya ; Shah, Bijal. / Guidelines Insights : Acute Lymphoblastic Leukemia, Version 1.2019. In: Journal of the National Comprehensive Cancer Network : JNCCN. 2019 ; Vol. 17, No. 5. pp. 414-423.
@article{5a5956df881d4dcf9e57f8835d271406,
title = "Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019",
abstract = "Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.",
author = "Brown, {Patrick A.} and Matthew Wieduwilt and Aaron Logan and DeAngelo, {Daniel J.} and Wang, {Eunice S.} and Amir Fathi and Cassaday, {Ryan D.} and Litzow, {Mark R} and Anjali Advani and Patricia Aoun and Bhavana Bhatnagar and Boyer, {Michael W.} and Teresa Bryan and Burke, {Patrick W.} and Coccia, {Peter F.} and Coutre, {Steven E.} and Nitin Jain and Suzanne Kirby and Arthur Liu and Stephanie Massaro and Mattison, {Ryan J.} and Olalekan Oluwole and Nikolaos Papadantonakis and Jae Park and Rubnitz, {Jeffrey E.} and Uy, {Geoffrey L.} and Gregory, {Kristina M.} and Ndiya Ogba and Bijal Shah",
year = "2019",
month = "5",
day = "1",
doi = "10.6004/jnccn.2019.0024",
language = "English (US)",
volume = "17",
pages = "414--423",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Guidelines Insights

T2 - Acute Lymphoblastic Leukemia, Version 1.2019

AU - Brown, Patrick A.

AU - Wieduwilt, Matthew

AU - Logan, Aaron

AU - DeAngelo, Daniel J.

AU - Wang, Eunice S.

AU - Fathi, Amir

AU - Cassaday, Ryan D.

AU - Litzow, Mark R

AU - Advani, Anjali

AU - Aoun, Patricia

AU - Bhatnagar, Bhavana

AU - Boyer, Michael W.

AU - Bryan, Teresa

AU - Burke, Patrick W.

AU - Coccia, Peter F.

AU - Coutre, Steven E.

AU - Jain, Nitin

AU - Kirby, Suzanne

AU - Liu, Arthur

AU - Massaro, Stephanie

AU - Mattison, Ryan J.

AU - Oluwole, Olalekan

AU - Papadantonakis, Nikolaos

AU - Park, Jae

AU - Rubnitz, Jeffrey E.

AU - Uy, Geoffrey L.

AU - Gregory, Kristina M.

AU - Ogba, Ndiya

AU - Shah, Bijal

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

AB - Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

UR - http://www.scopus.com/inward/record.url?scp=85066289260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066289260&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0024

DO - 10.6004/jnccn.2019.0024

M3 - Article

C2 - 31085755

AN - SCOPUS:85066289260

VL - 17

SP - 414

EP - 423

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -